Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$884.74 USD

884.74
1,163,785

-6.33 (-0.71%)

Updated Oct 3, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN

Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Mark Vickery headshot

Jobless Claims Still High but Coming Down, Plus More Q1 Results

4.427 million new jobless claims were made in the past week, bringing the total of the past 5 weeks of new claims data to north of 26 million workers in the U.S.

Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits

Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.

Economic Data Deluge

Economic Data Deluge

Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of 12.90% and 6.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke

The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

Sanofi (SNY) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.

Is a Surprise Coming for Lilly (LLY) This Earnings Season?

Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?

Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.

The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy

The Zacks Analyst Blog Highlights: Netflix, Silgan, Citrix Systems, Eli Lilly and FirstEnergy

Nalak Das headshot

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly

In addition to the Q1 earnings scorecard, today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Oracle (ORCL) and Eli Lilly (LLY).

Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?

Investments in HBO Max for its upcoming launch are likely to get reflected in AT&T's (T) bottom line in the first quarter of 2020.

Will Communications Segment Buoy AT&T's (T) Q1 Earnings?

Healthy momentum in wireless business on the back of 5G deployments is likely to get reflected in AT&T's (T) first-quarter 2020 earnings.

Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?

Ericsson's (ERIC) first-quarter performance is likely to have benefited from momentum in business led by its strategy to increase investments for technology leadership, including 5G.

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

Nalak Das headshot

5 Top Must-Buy Stocks Set to Beat on Q1 Earnings This Week

Despite the coronavirus-led economic disaster, five stocks with a favorable Zacks Rank are set to beat Q1 earnings estimates this week.

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts

J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines

Nalak Das headshot

Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Begins Enrollment in Study for Severe Coronavirus Infection

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

CytoDyn's Leronlimab Progressing Well in Coronavirus Program

CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.